Picture of Dermata Therapeutics logo

DRMA Dermata Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Annual cashflow statement for Dermata Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSPROSPECTUS10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-4.72-3.24-7.9-9.61-7.79
Depreciation
Non-Cash Items0.873-0.0361.920.930.522
Unusual Items
Other Non-Cash Items
Changes in Working Capital-0.075-0.7560.29-0.1540.864
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-3.92-4.03-5.69-8.83-6.41
Financing Cash Flow Items-0.0120-0
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities4.732.57164.287.61
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash0.812-1.4610.3-4.561.2